By: Benzinga
Morgan Stanley Reiterates Overweight Rating on Watson Pharmaceuticals
In a report published Monday, Morgan Stanley reiterated its Overweight rating on Watson Pharmaceuticals (NYSE: WPI ). Morgan Stanley noted, “We did not know that Covidien was pursuing generic Concerta (we were not aware of any Paragraph IV litigation), nor that it would qualify for exclusivity on the 27, 36,
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here